GENFIT Secures €185 Million Royalty Financing Deal to Bolster R&D and Financial Stability

Genfit SA ( (GNFT) ) has shared an update.

On January 30, 2025, GENFIT announced a significant non-dilutive royalty financing agreement with HealthCare Royalty (HCRx) worth up to €185 million, aimed at strengthening their financial position by extending their cash runway beyond 2027. The deal includes an immediate €130 million upfront payment and potential additional instalments, contingent on meeting certain milestones. This agreement is expected to bolster GENFIT’s capacity to advance its Acute-on-Chronic Liver Failure (ACLF) pipeline while eliminating its convertible debt overhang through the proposed repurchase of 2025 OCEANE bonds.

More about Genfit SA

GENFIT S.A. is a late-stage biopharmaceutical company focused on developing therapeutic solutions for patients with rare and life-threatening liver diseases. The company is engaged primarily in the biopharmaceutical industry, with a strategic partnership with Ipsen to develop and commercialize treatments such as Iqirvo® (elafibranor) for Primary Biliary Cholangitis (PBC).

YTD Price Performance: -2.61%

Average Trading Volume: 8,208

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $179.6M

Learn more about GNFT stock on TipRanks’ Stock Analysis page.